Thyrocare TechnologiesNSE:THYROCARE -3.71%87 Current Ratio is 3.39 as of Mar. 2026, which is 2% below its 10-year median of 3.47. GuruFocus rates NSE:THYROCARE with a GF Score™ of 87/100 and a GF Value™ of ₹395.01 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Thyrocare Technologies ranks better than 71.83% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Thyrocare Technologies's current ratio for the quarter that ended in Mar. 2026 was 3.39.
Thyrocare Technologies has a current ratio of 3.39. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Thyrocare Technologies's Current Ratio or its related term are showing as below:
NSE:THYROCARE'
s Current Ratio Range Over the Past 10 Years
Min: 1.86 Med: 3.47 Max: 8.49
Current: 3.39
During the past 13 years, Thyrocare Technologies's highest Current Ratio was 8.49. The lowest was 1.86. And the median was 3.47.
NSE:THYROCARE's Current Ratio is ranked better than 71.83% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.1
vs NSE:THYROCARE: 3.39
Thyrocare Technologies (NSE:THYROCARE) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Thyrocare Technologies Current Ratio Related Terms
Thyrocare Technologies Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:THYROCARE vs TMO, DHR, IDXX: Current Ratio Comparison
For the Diagnostics & Research subindustry, Thyrocare Technologies's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thyrocare Technologies Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thyrocare Technologies's Current Ratio distribution charts can be found below:
* The bar in red indicates where Thyrocare Technologies's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thyrocare Technologies (NSE:THYROCARE) has a Current Ratio of 3.39 as of Mar. 2026. This is near median its historical median of 3.47. Over the past decade, Thyrocare Technologies' Current Ratio has ranged from 1.86 to 8.49. According to the industry distribution chart, Thyrocare Technologies ranks #60 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 28.2%.
Is Thyrocare Technologies' Current Ratio too high?
Thyrocare Technologies' current Current Ratio of 3.39 is near median its 10-year median of 3.47. Over the past 10 years, this metric has ranged from a low of 1.86 to a high of 8.49. The Medical Diagnostics & Research industry median Current Ratio is 2.10. Thyrocare Technologies' value of 3.39 is 61.4% above this industry median. Based on the distribution chart, Thyrocare Technologies ranks #60 out of 213 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Thyrocare Technologies has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' Current Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Thyrocare Technologies ranks #60 out of 213 companies for Current Ratio. This puts Thyrocare Technologies in the upper half of its industry. The industry median Current Ratio is 2.10. Thyrocare Technologies' value of 3.39 is 61.4% above this benchmark. Historically, Thyrocare Technologies' own Current Ratio has ranged from 1.86 to 8.49 over the past decade. While the company's 10-year median is 3.47 vs. the industry median of 2.10, Thyrocare Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 2.10, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thyrocare Technologies's current Current Ratio of 3.39 is 61.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 2.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thyrocare Technologies's current Current Ratio is 3.39, which is near median its own 10-year median of 3.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (NSE:THYROCARE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹395.01, compared to a current price of ₹515.70 — trading 30.6% above its estimated fair value. The current Current Ratio is 3.39, which is near median its 10-year median of 3.47 and 61.4% above the Medical Diagnostics & Research industry median of 2.10. Thyrocare Technologies' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Thyrocare Technologies (NSE:THYROCARE), the current Current Ratio is 3.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thyrocare Technologies (NSE:THYROCARE) Overvalued in 2026?
Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued.
The current stock price of ₹515.70 is trading 30.6% above its estimated GF Value™ of ₹395.01.
GuruFocus considers Thyrocare Technologies to be Significantly Overvalued.
Key valuation signals for NSE:THYROCARE:
Current Ratio: 3.39 (near median its 10-year median of 3.47)
GF Value™: ₹395.01 vs. price of ₹515.70 (30.6% above fair value)
Industry Position: 61.4% above the Medical Diagnostics & Research median (#60 of 213)
No single metric tells the full story. See the NSE:THYROCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
87GF Score
Get the complete analysis for NSE:THYROCARE
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:THYROCARE has been successfully added to your 
